A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

Launched by SINOTAU PHARMACEUTICAL GROUP ·

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called Flotufolastat F-18 Injection, which helps doctors take detailed pictures of the prostate using a special type of scan called a PET scan. The goal is to see if this agent is safe and how it behaves in the body, especially in healthy older adults. This study is important because it may improve how prostate cancer is detected in the future.

The trial is looking for healthy adults, including both men and women, aged between 65 and 74 years old. If you join, you can expect to receive the Flotufolastat F-18 Injection and then undergo scans to track where the agent goes in your body and how much radiation you receive. The study will also monitor your health closely to make sure the injection is safe and well-tolerated. This is an early-phase trial, so it’s focused mainly on safety and how the agent moves through the body rather than treating disease.

Gender

ALL

Eligibility criteria